Arcinova, a Quotient Sciences company, operates from state-of-the-art facilities in Alnwick and Reading, UK. The company offers comprehensive services across the drug development lifecycle, from early-phase development through to clinical trials. With a strong emphasis on scientific excellence and regulatory compliance, Arcinova supports pharmaceutical and biotechnology clients in advancing their molecules efficiently and effectively.

Key Products and Services

• Drug Substance Synthesis & Manufacturing: Arcinova streamlines drug substance supply from candidate to early clinical stages, bridging gaps with solid-state and phase-appropriate analytics, ensuring IMPD/IND readiness.

• Drug Product Services: The company develops scalable formulations for oral, inhaled, and parenteral delivery, tailored to each molecule’s target product profile and development stage.

• Isotope Labelling: Arcinova provides precision-labelled compounds for pre-clinical and human ADME studies, enabling accurate pharmacokinetic and metabolic pathway analysis.

• Bioanalysis: The company delivers rapid, regulatory-compliant quantification of drugs, metabolites, and biomarkers using advanced LC-MS/MS and ICP-MS platforms.

Arcinova’s commitment to innovation and quality, combined with its integration into the Quotient Sciences network, positions it as a trusted partner for companies seeking to accelerate the development of new medicines. Through its comprehensive service offerings and scientific expertise, Arcinova continues to play a pivotal role in advancing drug development globally.